Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Osteopontin
100%
Targeted Therapy
100%
Primary Central Nervous System Lymphoma (PCNSL)
100%
Agelastatin A
61%
Ethyl
53%
Chloro
53%
Phase I Trial
15%
Therapeutic Action
15%
Osteopontin Expression
15%
Brain Tumor
15%
Cerebral Tumor
7%
Strong Correlation
7%
Lymphoma Cells
7%
Therapeutic Applications
7%
GLP Study
7%
Mouse Xenograft Model
7%
Dose-limiting Toxicity
7%
CNS Penetration
7%
Progression-free Survival
7%
Orphan Disease
7%
Vehicle Control
7%
Preclinical Development
7%
Tumor Dissemination
7%
Glioblastoma multiforme
7%
High Penetrance
7%
Murine Model
7%
Overall Incidence
7%
Upregulated Genes
7%
Multifaceted Roles
7%
Immunohistochemical Analysis
7%
Lymphoma Patients
7%
Generated Datasets
7%
In Vivo Activity
7%
Care-control
7%
Metastatic Breast Cancer
7%
Unmet
7%
Overall Survival
7%
Aggressive Tumor
7%
Fast-track Approval
7%
Primary Brain Tumor
7%
Therapeutic Needs
7%
Non-CNS
7%
Tumor Invasion
7%
Pro-tumorigenic
7%
IND Application
7%
Molecular Abnormalities
7%
Specific Aims
7%
Tumor Growth
7%
First-in-class
7%
Standard of Care
7%
Functional Genomics
7%
Secondary Brain Tumor
7%
Gene Expression Analysis
7%
High-dose Methotrexate (HD-MTX)
7%
Pharmacology, Toxicology and Pharmaceutical Science
Primary Central Nervous System Lymphoma
100%
Osteopontin
100%
Intracranial Tumor
50%
Mouse Model
12%
Clinical Trial Design
12%
Therapeutic Use
12%
Clinical Trial
12%
Tumor Growth
12%
Methotrexate
12%
Rat
12%
Progression Free Survival
12%
Overall Survival
12%
Glioblastoma
12%
Metastatic Breast Cancer
12%
Diseases
12%
Tumor Invasion
12%